The vote for best biotech CEO goes to…

Who's the best CEO in biotech? TheStreet posed that question to its readers and came up with Matthew Emmens, who helms Vertex ($VRTX). Vertex has had a big year, of course, with the successful launch of Incivek, the new standard of care for hepatitis C. But no sooner had that treatment hit the market than analysts turned to the pipeline looking for the next-gen program most likely to achieve success, and that persuaded TheStreet's Adam Feuerstein to declare that Pharmasset CEO Schaefer Price was even more deserving of recognition after orchestrating an $11 billion buyout deal with Gilead. Of course, Gilead CEO John Martin was also nominated by Feuerstein as one of the worst CEOs of the year. (Mitch Gold at Dendreon won that vote.) Maybe opposites attract in this business. Story

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.